Rapport Therapeutics, Inc. (RAPP)
| Market Cap | 2.34B +328.3% |
| Revenue (ttm) | 20.00M |
| Net Income | -137.16M |
| EPS | -3.05 |
| Shares Out | 47.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 332,725 |
| Open | 50.15 |
| Previous Close | 50.83 |
| Day's Range | 48.37 - 50.68 |
| 52-Week Range | 14.11 - 52.93 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 62.05 (+27.23%) |
| Earnings Date | Aug 5, 2026 |
About RAPP
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company’s lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorde... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for RAPP stock is "Strong Buy." The 12-month stock price target is $62.05, which is an increase of 27.23% from the latest price.
News
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and de...
Rapport Therapeutics price target raised to $75 from $68 at Raymond James
Raymond James analyst Tiago Fauth raised the firm’s price target on Rapport Therapeutics (RAPP) to $75 from $68 and keeps a Strong Buy rating on the shares. Rapport’s RAP-219 bipolar…
Rapport Therapeutics price target raised to $66 from $40 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Rapport Therapeutics (RAPP) to $66 from $40 and keeps a Buy rating on the shares after speaking with management.
Rapport Therapeutics reports Q2 EPS ($1.19), consensus (99c)
“We remain focused on disciplined execution as we deliver against several important catalysts this year,” said Abraham N. Ceesay, chief executive officer of Rapport. “With FOCUS 1 and FOCUS 2…
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026 Pipeli...
Rapport Therapeutics Earnings release: Q2 2026
Rapport Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Rapport Therapeutics Quarterly report: Q2 2026
Rapport Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Rapport Therapeutics Slides: Corporate presentation
Rapport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Rapport Therapeutics initiated with an Outperform at William Blair
William Blair initiated coverage of Rapport Therapeutics (RAPP) with an Outperform rating and $79.03 fair value estimate. Rapport is a clinical-stage leader in developing therapies targeting receptor-...
Rapport Therapeutics management to meet with Citizens
Meeting to be held in Boston on July 21 hosted by Citizens.
Rapport Therapeutics Slides: Corporate presentation
Rapport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Rapport Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Rapport Therapeutics (RAPP) with an Outperform rating and $52 price target The epilepsy market is attractive due to efficient drug development, predictable translation fr...
Rapport Therapeutics management to meet with Citizens
Meeting to be held in Boston on June 23 hosted by Citizens.
Rapport Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and proceeded with the election of three directors and the ratification of the audit firm, both of which were approved by stockholders. No additional nominations or questions were received, and all proposals passed as recommended.
Rapport Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Phase III trials for RAP-219 in focal-onset seizures are enrolling globally, supported by strong phase II data and a China partnership to accelerate recruitment. The pipeline includes upcoming trials in bipolar mania, primary generalized tonic-clonic seizures, and pain, with a cash runway into 2029.
Rapport Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
RAP-219, a precision neuroscience asset, is advancing through phase III trials for focal epilepsy, with strong phase II efficacy and a robust safety focus. A long-acting injectable is in development, and pivotal data for bipolar mania and open label extension are expected in Q4.
Rapport Therapeutics price target raised to $65 from $53 at BTIG
BTIG raised the firm’s price target on Rapport Therapeutics (RAPP) to $65 from $53 and keeps a Buy rating on the shares. The firm is citing clinical execution behind its…
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and dev...
Rapport Therapeutics assumed with a Buy at Truist
Truist assumed coverage of Rapport Therapeutics (RAPP) with a Buy rating with a price target of $56, up from $44. The firm’s thesis is largely consistent with its most recently…
Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)
Reports Q1 revenue $20,000, consensus $6M. “We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling new follow-up Phase 2a data recently presented at AAN...
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RA...
Rapport Therapeutics Earnings release: Q1 2026
Rapport Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Rapport Therapeutics Quarterly report: Q1 2026
Rapport Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Rapport Therapeutics Slides: Corporate presentation
Rapport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Modalités de mise à disposition du rapport financier annuel 2025
MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 La société AdVini annonce avoir mis à la disposition du public et déposé auprès de l'Autorité des Marchés Financiers son Rapport Financ...